Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
US Department of Justice
Johnson and Johnson
Argus Health

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,859,021

« Back to Dashboard

Summary for Patent: 5,859,021

Title: Antiviral combinations
Abstract:Combinations comprising a compound of formula (1) ##STR1## or a pharmaceutically acceptable derivative thereof and an inhibitor of HIV replication, pharmacetical formulations thereof and their use in the treatment of HIV infections.
Inventor(s): Cameron; Janet Mary (Greenford, GB), Cammack; Nicholas (Greenford, GB)
Assignee: Glaxo Group Limited (Greenford, GB)
Application Number:08/605,610
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,859,021

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9110624May 16, 1991
United Kingdom9121381Oct 08, 1991
United Kingdom9123581Nov 06, 1991

International Patent Family for Patent: 5,859,021

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
United Kingdom9121381► Subscribe
United Kingdom9110624► Subscribe
Czech Republic285232► Subscribe
Germany19875016► Subscribe
Germany69206876► Subscribe
Spain2083668► Subscribe
European Patent Office0513917► SubscribeC980018Netherlands► Subscribe
European Patent Office0513917► SubscribeSPC/GB98/019United Kingdom► Subscribe
European Patent Office0513917► Subscribe98C0018Netherlands► Subscribe
European Patent Office0513917► Subscribe98C0020Belgium► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: